RedHill Biopharma Limited
Quick facts
Phase 3 pipeline
- RHB-102 · Gastrointestinal
RHB-102 is a gastric motility agent. - RHB-104 · Gastroenterology / Immunology
RHB-104 is a combination of three antibiotics (clarithromycin, rifabutin, and clofazimine) designed to target Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease. - RHB-105 · Infectious Diseases
RHB-105 is a combination of rifabutin and hyoscyamine for the treatment of COVID-19. - Rifamycin SV MMX · Gastroenterology / Infectious Disease
Rifamycin SV MMX is a modified-release antibiotic that targets bacterial RNA polymerase to inhibit bacterial protein synthesis, with enhanced delivery to the colon.
Phase 2 pipeline
- BEKINDA · Gastroenterology
Bekinda is a delayed-release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: